MabVax to Present at BIO CEO & Investor Conference

- Live audio webcast presentation on Monday, February 12, 2018 at 11:15 a.m. EST -

SAN DIEGO, Feb. 7, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) ("MabVax" or the "Company"), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that David Hansen, MabVax's President and Chief Executive Officer will present at the BIO CEO & Investor Conference on Monday, February 12, 2018 at 11:15 a.m. EST in New York, NY.

MabVax Therapeutics Logo (PRNewsfoto/MabVax Therapeutics Holdings, I)

As part of his presentation, Mr. Hansen will provide a corporate overview, including a clinical update on the Company's two lead clinical development programs: (1) Its fully human antibody therapeutic product, MVT-5873, currently in a Phase 1 clinical study in combination with gemcitabine and nab-paclitaxel in first line therapy for the treatment of newly diagnosed pancreatic cancer patients. The Company remains on track to announce interim safety and response data from the MVT-5873 study early in the first quarter of 2018; and (2) the MVT-1075 program, a human antibody-based radioimmunotherapy ("RIT") product, currently being evaluated in a Phase 1 clinical trial for the treatment of pancreatic, colon and lung cancers. MabVax recently announced the completion of enrollment and dosing of all patients in the initial cohort of the Phase 1 MVT-1075 study and plans to report interim results from this study in the first quarter of 2018.  

In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To schedule a meeting, please contact the Company through the one-on-one meeting portal.

A live audio webcast of the presentation will be available on the Events page of the Investor section of the Company's website ( A webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days following the live presentation.

About MabVax

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors. CA19-9 is expressed in over 90% of pancreatic cancers and in other diseases including small cell lung and GI cancers. CA19-9 plays an important role in tumor adhesion and metastasis and is a marker of an aggressive cancer phenotype. CA19-9 serum levels are considered a valuable adjunct in the diagnosis, prognosis and treatment monitoring of pancreatic cancer. With our collaborators including Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute, Honor Health and Imaging Endpoints, we have treated more than 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase 1 clinical studies and demonstrated early safety and specificity for the target. Patient dosing has commenced for our lead development program in Phase 1 clinical study of the Company's radioimmunotherapy product MVT-1075. For additional information, please visit the Company's website,

Forward-Looking Statements

This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's clinical trials and product development pipeline. We have no assurance that all the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended and supplemented from time to time and the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Investor Contact:

Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475

Media Contact:

Travis Kruse, Ph.D.
Russo Partners LLC
Phone: +1 (212) 845-4272


Cision View original content with multimedia:

SOURCE MabVax Therapeutics Holdings, Inc.